Forecast

There is no analyst data available for this company.

News Go to news feed

Grupo Fleury beats revenue estimates, slightly misses EPS in Q1 2026

Grupo Fleury reported Q1 2026 revenue of USD 2.22 billion (+10.1% YoY), exceeding expectations, while earnings per share of USD 0.35 narrowly missed the USD 0.354 estimate by 1.13%. Growth was driven mainly by the B2C segment; gross profit and EBITDA also rose by double digits. The stock fell 1.49% after hours; management emphasizes further investment in innovation and expansion while monitoring macroeconomic and regulatory risks. » More on de.investing.com
Grupo Fleury reports double-digit revenue growth in Q1 2026 on 100th anniversary

Grupo Fleury posted revenue of R$2.4 billion in Q1 2026 (+10.1%), beating market expectations, while earnings per share of $0.35 slightly missed the $0.354 estimate. EBITDA rose to R$606.0 million (+10.7%) and net income to R$201.2 million (+12.2%), accompanied by a ROIC of 17% and a conservative leverage of 1.0x net debt/EBITDA. Management highlights successful diversification into an integrated health ecosystem, launched the Life‑Care offering, and expects further growth despite challenges in the B2B segment. » More on de.investing.com
Fleury reports double-digit revenue growth in Q4 2025 in its hundredth year

Grupo Fleury posted revenue growth of 12.2% in Q4 2025 to R$2.238bn and R$9.003bn for the full year (+8.2%). EBITDA rose 12.5% in the quarter to R$455.9m with a stable margin of 22.1%, and operating cash conversion was 99.9%; annual net income was R$612.8m. The company saw strong growth in the B2C segment and in New Links, maintains conservative leverage of 1.0x (net debt/EBITDA) and shows a high dividend yield of 10.65%. Despite results beating expectations, the stock fell after hours, reflecting profit-taking after last year’s strong run and uncertainty about sustainable growth rates. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Fleury SA has already paid €0.26 in dividends. The last payout was in December 2025.

Financials

In the last quarter, Fleury SA had revenue of €392.16M and net profit of €37.55M

(EUR)	June 2026	YoY
Revenue	392.16M	24.01%
Gross profit	100.32M	21.65%
Net profit	37.55M	57.86%
EBITDA	103.51M	13.24%

Fundamentals

Metric	Value
Market capitalization	€1.77B
Number of shares	543.62M
52-week high/low	€3.41 - €2.36
Dividend yield	5.84%
Dividends TTM	€0.19
Beta	0.21
P/E ratio	14.78
PEG ratio	0.86
P/B ratio	1.93
P/S ratio	1.19

Company profile

Fleury S.A. bietet zusammen mit seinen Tochtergesellschaften medizinische Dienstleistungen in den Bereichen Diagnose, Behandlung, klinische Analyse, Gesundheitsmanagement, medizinische Versorgung, Orthopädie und Augenheilkunde in Brasilien an. Das Unternehmen ist in drei Segmenten tätig: Diagnostische Medizin, Integrierte Medizin und Zahnmedizin. Es bietet Labor- und Bilduntersuchungen, diagnostische Informationen, Check-up und Referenzlabor, Genomik, Kliniktag, Infusionszentrum, zahnärztliche Bildgebungsuntersuchungen, zahnärztliche Radiologie und diagnostische Bildgebungsdienste. Das Unternehmen bietet auch Saúde I, eine digitale Gesundheitsplattform, die Dienstleistungen, einschließlich Telekonsultationen, medizinische, diagnostische Medizin Untersuchungen und Verfahren, und Unternehmenslösungen und Face-to-Face-Primärversorgung, sowie Lösungen für Ärzte mit digitalen Büro-und medizinische Ausbildung. Es betreibt 284 Kundendiensteinheiten und 31 krankenhausbasierte Einheiten unter den Markennamen Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ und Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA und Pretti und Bioclinic. Das Unternehmen wurde 1926 gegründet und hat seinen Hauptsitz in São Paulo, Brasilien.